HUTCHMED· @hutchmed · X·· 13 天前精选AI 评分50
AI 导读
和黄医药宣布,索乐匹尼布(sovleplenib)获美国FDA授予孤儿药资格,用于治疗自身免疫性溶血性贫血(AIHA)。这是该药在近期获得原发免疫性血小板减少症(ITP)孤儿药资格后,获得的第二个FDA孤儿药资格。
推荐理由
原文说明该药在ITP之后又获AIHA孤儿药资格,读者可据此了解其在美国的适应症拓展节奏。
正文
We are pleased to announce that, following its recent Orphan Drug Designation for primary immune thrombocytopenia (ITP) , sovleplenib has now been granted a second US FDA Orphan Drug Designation for autoimmune hemolytic anemia (AIHA). https://www.hutch-med.com/sovleplenib-fda-orphan-drug-aiha/
来源:HUTCHMED · x.com